Douglas Palmer

First Name*

Last Name*

Email*

Phone*

Message*

I am authorized to claim this profile. I agree Eventually may contact me regarding my request.

Your request has been received.
Thank you.

Oops! Something went wrong while submitting the form.

First Name*

Last Name*

Email*

Phone*

Message*

Douglas Palmer and Eventually may contact me regarding my request.

Your request has been received.
Thank you.

Oops! Something went wrong while submitting the form.

Contact Douglas

Douglas Palmer

Executive Director of Immuno-Oncology Translational Medicine

AstraZeneca

I am devoted to innovating and translating novel immunotherapies to treat metastatic cancer. In my two decades at the NCI with Steve Rosenberg and Nick Restifo, my work helped to uncover the mechanisms of immune maturation, T cell-host interactions, cancer targeting, and T cell exhaustion. I was fortunate to translate this work into the clinic where I led one of the first CRISPR gene editing clinical trials in the US in neoantigen-specific TIL. Now as the Executive Director of Immuno-Oncology at AstraZeneca, I lead efforts to improve our clinical line of sight, drive back translation, and enhance data access and centricity.

Talks About
#immunology #immunoassay #immunotherapy #immunooncology

Preferred Locations
#NorthAmerica

Speaking Engagements

11th Annual Tumor Models Boston Summit

Paid

The past year has seen several combination therapies entering Phase I and II clinical trials, with some showing promising results while others facing challenges, especially in the treatment of solid tumors. The FDA Modernization Act 2.0 has encouraged the biopharmaceutical industry to shift away from animal models, allowing for more innovation in p

12-13 July 2023

Healthcare

Claim Your Profile Request

Speaker Contact Request

SPEAKER

Douglas Palmer

Executive Director of Immuno-Oncology Translational Medicine

Speaking Engagements

11th Annual Tumor Models Boston Summit